Vanda Pharmaceuticals reports smaller Q3 loss, beats expectations

Vanda Pharmaceuticals Inc., headquartered in Washington, reported a third-quarter loss of $22.6 million, according to WTOP's coverage of Associated Press data. This amounted to a loss of 37 cents per share for the period.

The company's financial results exceeded Wall Street expectations, as analysts surveyed by Zacks Investment Research had predicted a larger loss of 72 cents per share. Vanda's revenue also surpassed forecasts, reaching $69.8 million compared to the expected $65.9 million.

These results indicate a better-than-anticipated financial performance for the Washington-based biopharmaceutical firm in the third quarter. The data was generated using Zacks Investment Research figures and reported by WTOP.

Investors and local stakeholders may view this as a positive sign for Vanda's ongoing operations in the Washington area and its position in the pharmaceutical industry.